In this scenario, we could hypothesize that the PCSK9i improve FCT by reducing LDL-C, while the SGLT2 probably increased FCT by reducing vascular inflammation and endothelial dysfunction. This evidence concerns the gene SLC5A2 and endothelial dysfunction.